Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-03-10 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab meddeler, at der er indsendt en supplerende registreringsansøgning til FDA for ofatumumab i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the submission of a supplemental Biologics License Application (sBLA) to the FDA for a drug candidate. It does not fit into financial reporting categories like 10-K or IR, nor is it a specific corporate action like a dividend or share buyback. As it is a general regulatory and corporate update regarding clinical trial progress and regulatory filings, it falls under the 'Regulatory Filings' (RNS) category.
2016-03-10 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) in Danish and details a specific business event: Genmab reaching a milestone payment from Janssen regarding the drug daratumumab. It announces a USD 5 million payment triggered by progress in a Phase II study for Non-Hodgkin Lymphoma (NHL). This type of announcement, focusing on a specific, non-periodic business development, partnership update, or material event, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it contained core financial results. Since it is a specific, non-periodic operational/partnership update rather than a comprehensive financial report (10-K, IR) or a standard earnings highlight (ER), and it is not a management change (MANG) or capital event (CAP), the most appropriate general category for a specific corporate announcement that doesn't fit other precise codes is Regulatory Filings (RNS). The length (7886 chars) is substantial, indicating it is the full announcement, not just a brief notice of publication (RPA).
2016-03-09 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a specific business event: Genmab receiving a USD 5 million milestone payment from Janssen related to the progress of the daratumumab clinical study in Non-Hodgkin's Lymphoma (NHL). This is a specific, material business update that is not a full financial report (10-K, IR), a transcript (CT), or a formal proxy/remuneration document (DEF 14A, PSI). It is a factual announcement regarding a collaboration milestone, which fits best under the general category of a significant business or regulatory update. Since it is not a standard earnings release (ER) or a specific capital/financing event (CAP), and it is a formal announcement, it aligns most closely with a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the milestone payment is viewed as revenue recognition, but RNS is the broader, safer category for non-standard corporate news releases that are not explicitly defined elsewhere. Given the nature of the announcement (milestone payment triggered by clinical progress), it is a material corporate event announcement, best classified as RNS (Regulatory Filings/General Announcement).
2016-03-09 English
Genmab når den anden milestone i samarbejdet med Janssen vedrørende daratumumab til behandling af NHL
Regulatory Filings Classification · 67% confidence The document is a corporate press release (“selskabsmeddelelse”) announcing that Genmab has reached a USD 5 million milestone payment from Janssen Biotech under their collaboration. It contains no actual financial statements, no meeting materials, no regulatory certifications, no board changes, no fundraising, and no detailed report. It therefore does not fit any specific report type (10-K, IR, ER, etc.) and is a general company announcement – the correct fallback category is Regulatory Filings (RNS).
2016-03-09 Danish
Genmab når den anden milestone i samarbejdet med Janssen vedrørende daratumumab til behandling af NHL
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a milestone payment received from a collaboration partner (Janssen). It details clinical trial progress and financial implications (a $5 million payment). This type of corporate news release, which is not a full financial report, proxy, or transcript, falls under the category of general regulatory announcements or corporate news updates. Given the specific nature of the announcement, 'RNS' (Regulatory Filings) is the most appropriate classification for this type of corporate disclosure.
2016-03-09 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and is dated March 9, 2016. It announces that Genmab has submitted an application to the European Medicines Agency (EMA) to expand the indication for ofatumumab based on Phase III study data (COMPLEMENT 2). This type of announcement, detailing a specific regulatory submission or clinical trial update that is not a full financial report (like 10-K or IR), typically falls under general regulatory news or investor relations updates. Since it is a specific announcement about a regulatory action (submission for marketing authorization change) and not a general trading update (RNS) or a formal financial report, it best fits the category for general regulatory/investor news. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-financial, non-management change announcements that are regulatory in nature, or 'Report Publication Announcement' (RPA) if it were announcing the publication of a report. Since this is an announcement *of an action* (submission) rather than the publication of a report, RNS is the best fit among the available codes for general corporate/regulatory news that doesn't fit a more specific category like MANG, DIV, or ER. However, considering the content is a specific corporate action update, and it is not a standard SEC filing, RNS (Regulatory Filings/General Announcement) serves as the best general category for this type of press release.
2016-03-09 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.